CytoReason and Summit Pharmaceuticals International Forge Commercial Alliance To Bring CytoReason’s Machine Learning Model of the Immune System for Drug Discovery & Development To Japanese Drug Makers

Sumitomo Corporation Group Statement for UK Modern Slavery Act 2015 (FY 2017 Statement)

Sumitomo Corporation Group Statement for UK Modern Slavery Act 2015 (FY 2016 Statement)

Successful Identification of Metabolite Differences in Urine between Healthy, Breast Cancer and Colorectal Cancer Groups

TRANSFER OF BUSINESS FROM SUMMIT PHARMACEUTICALS INTERNATIONAL TO SUMITOMO CORPORATION

Sumitomo Group to Advance into Cosmetic Materials Business in Europe -Acquiring Cosmetic Materials Business from Kyowa Hakko Europe GmbH-

Announcement of Business Transfer from Sumitomo Corporation to Summit Pharmaceuticals International Corporation